Table 1.
Patient Data
| Characteristics | All Patients (n = 29) | Patients Scanned at 3–6 Weeks of Treatment (n = 23) | Patients Scanned at 3–6 Weeks of Treatment in Survival Analysis (n = 12) | Patients Scanned at 2–4 Months of Treatment (n = 14; All in Survival Analysis) |
|---|---|---|---|---|
| Average age (years) ± SD | 42 ± 12 | 43 ± 11 | 40 ± 10 | 39 ± 13 |
| Sex (male/female) | 18/11 | 16/7 | 9/3 | 8/6 |
| Tumor location | ||||
| Hemisphere (left/right) | 17/12 | 13/10 | 6/6 | 7/7 |
| Frontal lobe | 19 | 15 | 7 | 9 |
| Temporal lobe | 7 | 5 | 4 | 5 |
| Parietal lobe | 3 | 3 | 1 | 0 |
| Tumor grade (2/3/4) | 19/7/3 | 14/6/3 | 4/6/2 | 9/4/1 |
| Number of recurrence (New/1st/2nd/3rd+) | 2/12/7/8 | 1/9/5/8 | 0/2/4/6 | 1/4/6/3 |
| 1p/19q co-deletion status (co-deleted/non-co-deleted/N/A) | 11/15/3 | 9/12/2 | 4/6/2 | 4/8/2 |
| IDH inhibitor drug (AG-120/AG-881) | 18/11 | 15/8 | 9/3 | 9/5 |
| Median progression-free survival in days and range (days) | 343 (23–1970) | 302 (23–1449) | 185 (23–580) | 320.5 (79–1970) |
| Median days between pretreatment scan date and start of IDH inhibitor treatment (days) | 9 (0–49) | 11 (0–33) | 7 (0–33) | 6.5 (0–49) |
| Median days between posttreatment scan date and treatment start date and range (days) | N/A | 27 (21–42) | 31 (23–42) | 113 (59–121) |
Abbreviation: IDH, isocitrate dehydrogenase.